Dr. Klaus Giese
Chief Scientific Officer
Pre-Clinical and Clinical Development of Atu027, a Liposomal siRNA, for Therapy in Oncology
Atu027, a novel RNAi therapeutic composed of liposomally formulated siRNA, is currently being tested in a Phase I clinical trial in oncology. This investigational drug targets the expression of PKN3 in the vascular endothelium and shows inhibition of tumor growth and strong anti-metastatic activity in various pre-clinical models. Latest developments on Atu027 will be discussed.